| LDOS |
Report |
Q2 2026 Revenue |
IN-LINE |
pred ~$4.44B vs. cons ~$4.43B |
MEDIUM |
| LDOS |
Report |
Q2 2026 Non-GAAP Diluted EPS |
BEAT |
pred ~$2.98 vs. cons ~$2.90 |
MEDIUM |
| LDOS |
Report |
Health segment operating margin |
MISS |
pred ~20.5% vs. cons ~22.5% |
LOW |
| LDOS |
Guide |
FY2026 Revenue guidance |
UNCHANGED |
guide ~$18.2B vs. cons ~$18.15B (FY2026) |
MEDIUM |
| LDOS |
Guide |
FY2026 Non-GAAP EPS guidance |
UNCHANGED |
guide ~$12.30 vs. cons ~$12.28 (FY2026) |
MEDIUM |
| LDOS |
Guide |
Health segment forward outlook / DHA-MHS GENESIS revenue impact commentary |
LOWER |
guide ~-$150M incremental Health revenue headwind vs. cons ~$0 baked in (FY2026-FY2027) |
LOW |
| LDOS |
Guide |
Book-to-bill ratio |
UNCHANGED |
guide ~1.0x for Q2 vs. cons/TTM ~1.1x (Q2 2026 / TTM) |
LOW |
| LDOS |
Guide |
Second-half reacceleration narrative (Q3/Q4 revenue & margin step-up) |
UNCHANGED |
guide reaffirmed H2 acceleration vs. cons already assuming H2 ramp (FY2026 H2) |
MEDIUM |
| LDOS |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| LDOS |
Return |
5-day cumulative residual |
-4.0% (FADE) |
Headline Q2 revenue/EPS likely land in-line-to-slightly-better since management pre-announced softness and consensus already de-risked, so any initial pop from a clean beat/reaffirm is likely modest. But the Health segment — hit directly by the DHA/MHS GENESIS integrator transition (Philips/Amwell exiting end of July, Oracle Health by November) — is where the real out-period math lives: even a reaffirmed FY26 headline (propped up by Entrust) likely comes with incremental, quantified FY26/FY27 Health revenue and margin headwinds that sell-side hadn't fully modeled. As analysts update models over the following days, implicit cuts to FY27 Health margin/EPS get layered in even if Q2 itself 'beats,' producing a fade as the market re-prices the structural margin risk in the higher-margin Health book rather than the transitory Q2 dip that had already been guided. |
MEDIUM |